Lysogene SA

While 2023 saw several cell and gene therapy approvals that were genuine scientific and clinical breakthroughs, many smaller companies in the sector bore the brunt of the ongoing biopharma downturn. M

Patient advocates, sponsors and clinical experts are protesting what they view as generally unworkable recommendations from the US Food and Drug Administration on development approaches and clinical t

Avrobio has announced that it is to halt all drug development in its gene therapy pipeline, and begin a “comprehensive exploration of strategic alternatives” to maximize shareholder value. The Cambri

The sun shined on the first and last days of the J.P. Morgan Healthcare Conference, held 9-12 January in San Francisco, and the rain, winds and downed trees that soaked and blocked the paths of the me